Table 2 Relationships between lipid metabolism and chemosensitivity
| Â | pCR | OR | ||||
|---|---|---|---|---|---|---|
Negative | Positive | P value | Negative | Positive | P value | |
All breast cancer (n = 327) | ||||||
TC (preNAC) | 0.626 | Â | Â | 0.242 | ||
 Normal | 98 (54.1%) | 63 (57.8%) | 13 (44.8%) | 148 (56.7%) | ||
 High | 83 (45.9%) | 46 (42.2%) | 16 (55.2%) | 113 (43.3%) | ||
TG (preNAC) | 0.299 | Â | Â | 0.866 | ||
 Normal | 139 (76.8%) | 88 (82.2%) | 24 (80.0%) | 203 (78.7%) | ||
 High | 42 (23.2%) | 19 (17.8%) | 6 (20.0%) | 55 (21.3%) | ||
TC (postNAC) | 0.703 | Â | Â | 0.952 | ||
 Normal | 72 (43.4%) | 47 (46.5%) | 11 (44.0%) | 108 (44.6%) | ||
 High | 94 (56.6%) | 54 (53.5%) | 14 (56.0%) | 134 (55.4%) | ||
TG (postNAC) | 0.694 | Â | Â | 0.667 | ||
 Normal | 88 (55.7%) | 56 (59.0%) | 15 (62.5%) | 129 (56.3%) | ||
 High | 70 (44.3%) | 39 (41.0%) | 9 (37.5%) | 100 (43.7%) | ||
Luminal (n = 108) | ||||||
TC (preNAC) | 0.795 | Â | Â | 0.728 | ||
 Normal | 43 (55.1%) | 9 (50.0%) | 4 (44.4%) | 48 (55.2%) | ||
 High | 35 (44.9%) | 9 (50.0%) | 5 (55.6%) | 39 (44.8%) | ||
TG (preNAC) | 0.347 | Â | Â | 0.680 | ||
 Normal | 60 (76.9%) | 16 (88.9%) | 8 (88.9%) | 68 (78.2%) | ||
 High | 18 (23.1%) | 2 (11.1%) | 1 (11.1%) | 19 (21.8%) | ||
TC (postNAC) | 0.415 | Â | Â | 0.707 | ||
 Normal | 27 (35.5%) | 8 (47.1%) | 2 (28.6%) | 33 (38.4%) | ||
 High | 49 (64.5%) | 9 (52.9%) | 5 (71.4%) | 53 (61.6%) | ||
TG (postNAC) | 0.785 | Â | Â | 0.685 | ||
 Normal | 42 (57.5%) | 11 (64.7%) | 4 (66.7%) | 49 (58.3%) | ||
 High | 31 (42.5%) | 6 (35.3%) | 2 (33.3%) | 35 (41.7%) | ||
Luminal-HER (n = 42) | ||||||
TC (preNAC) | 0.766 | Â | Â | 1.000 | ||
 Normal | 14 (58.3%) | 7 (63.6%) | 3 (60.0%) | 18 (60.0%) | ||
 High | 10 (41.7%) | 4 (36.4%) | 2 (40.0%) | 12 (40.0%) | ||
TG (preNAC) | 0.076 | Â | Â | 0.109 | ||
 Normal | 17 (68.0%) | 11 (100.0%) | 3 (50.0%) | 25 (83.3%) | ||
 High | 8 (32.0%) | 0 (0.0%) | 3 (50.0%) | 5 (16.7%) | ||
TC (postNAC) | 1.000 | Â | Â | 0.330 | ||
 Normal | 10 (50.0%) | 5 (50.0%) | 1 (20.0%) | 14 (56.0%) | ||
 High | 10 (50.0%) | 5 (50.0%) | 4 (80.0%) | 11 (44.0%) | ||
TG (postNAC) | 0.130 | Â | Â | 0.144 | ||
 Normal | 9 (45.0%) | 7 (77.8%) | 1 (20.0%) | 15 (62.5%) | ||
 High | 11 (55.0%) | 2 (22.2%) | 4 (80.0%) | 9 (37.5%) | ||
HER2-enriched (n = 72) | ||||||
TC (preNAC) | 0.436 | Â | Â | 0.750 | ||
 Normal | 14 (53.9%) | 25 (65.8%) | 1 (50.0%) | 38 (61.3%) | ||
 High | 12 (46.1%) | 13 (34.2%) | 1 (50.0%) | 24 (38.7%) | ||
TG (preNAC) | 0.835 | Â | Â | 0.323 | ||
 Normal | 20 (80.0%) | 28 (77.8%) | 2 (100.0%) | 46 (78.0%) | ||
 High | 5 (20.0%) | 8 (22.2%) | 0 (0.0%) | 13 (22.0%) | ||
TC (postNAC) | 0.792 | Â | Â | 0.521 | ||
 Normal | 15 (60.0%) | 21 (63.6%) | 2 (100.0%) | 34 (60.7%) | ||
 High | 10 (40.0%) | 12 (36.4%) | 0 (0.0%) | 22 (39.3%) | ||
TG (postNAC) | 0.779 | Â | Â | 0.719 | ||
 Normal | 15 (65.2%) | 18 (60.0%) | 1 (50.0%) | 32 (62.8%) | ||
 High | 8 (34.8%) | 12 (40.0%) | 1 (50.0%) | 19 (37.2%) | ||
TNBC (n = 105) | ||||||
TC (preNAC) | 0.889 | Â | Â | 0.378 | ||
 Normal | 27 (50.9%) | 22 (52.4%) | 5 (38.5%) | 44 (53.7%) | ||
 High | 26 (49.1%) | 20 (47.6%) | 8 (61.5%) | 38 (46.3%) | ||
TG (preNAC) | 0.936 | Â | Â | 0.729 | ||
 Normal | 42 (79.3%) | 33 (78.6%) | 11 (84.6%) | 64 (78.1%) | ||
 High | 11 (20.7%) | 9 (21.4%) | 2 (15.4%) | 18 (21.9%) | ||
TC (postNAC) | 0.270 | Â | Â | 0.322 | ||
 Normal | 20 (44.5%) | 13 (31.7%) | 6 (54.6%) | 27 (36.0%) | ||
 High | 25 (55.6%) | 28 (68.3%) | 5 (45.4%) | 48 (64.0%) | ||
TG (postNAC) | 0.921 | Â | Â | 0.049 | ||
 Normal | 22 (52.4%) | 20 (51.3%) | 9 (81.8%) | 33 (47.1%) | ||
 High | 20 (47.6%) | 19 (48.7%) | 2 (18.2%) | 37 (52.9%) | ||